TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28284221

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive method (DMPA, oral pills, norplant)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Existing users of hormonal contraceptives
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: New users of hormonal contraceptives
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Younger women (≤30 years)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Women not using contraceptives at baseline due to lack of access or money, breastfeeding, or other reasons
Number of subjects: 807
Study: 25962707

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: HbA1c (impaired fasting glucose)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: HbA1c (normal glucose)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: HbA1c threshold of 40 mmol/mol (5.8%)
Number of subjects: 2079
Study: 23585423

Group type: EXPERIMENTAL
Intervention: Enalapril at 0.4 mg/kg/day for 1 year
Number of subjects: 41

Group type: COMPARATOR
Intervention: No enalapril (control)
Number of subjects: 41
Study: 21436391

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 8
Study: 19738137

Group type: EXPERIMENTAL
Intervention: Dietary vitamin K-guided strategy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 132
Study: 17694046

Group type: EXPERIMENTAL
Intervention: Intraligamental injection (ITR)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Infiltration injection (IFL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No local anaesthetic (NLA)
Number of subjects: 54
Study: 15037668

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine therapy at a rate of 4 mg/h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine (2 to 5 mg per inhalation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 3 mg subcutaneous apomorphine
Number of subjects: 9

Group type: COMPARATOR
Intervention: 30 mg sublingual apomorphine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg rectal apomorphine suppository
Number of subjects: 9
Study: 11232013

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg bd
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg bd
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 10689659

Group type: EXPERIMENTAL
Intervention: Active electrical stimulation
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Most effective group
Number of subjects: 265

Group type: COMPARATOR
Intervention: Inactive groups (placebo)
Number of subjects: 265
Study: 7817151

Group type: EXPERIMENTAL
Intervention: Frequent teeth brushing and use of fluoride toothpaste
Number of subjects: 671

Group type: COMPARATOR
Intervention: Less frequent teeth brushing and less use of fluoride toothpaste
Number of subjects: 671
Study: 3165190

Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters, replaced on days 3 and 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters, replaced on days 1 and 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chemomechanical preparation (3% H2O2 and 5.25% NaOCl as irrigants, no intracanal medication)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chemomechanical preparation
Number of subjects: 15
Study: 29600670

Group type: EXPERIMENTAL
Intervention: Arthroscopic group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional section group
Number of subjects: 49
Study: 27842579

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) before surgical consultation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 180
Study: 25341453

Group type: EXPERIMENTAL
Intervention: fMRI-guided microsurgery
Number of subjects: 600

Group type: COMPARATOR
Intervention: standard microsurgery
Number of subjects: 600
Study: 23519055

Group type: EXPERIMENTAL
Intervention: High TYRP1/S100B mRNA ratio
Number of subjects: 104
Study: 21358087

Group type: EXPERIMENTAL
Intervention: RT-HT (Radiation Therapy with Hyperthermia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: RT alone (Radiation Therapy)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RT-HT
Number of subjects: 56

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 56
Study: 18855232

Group type: EXPERIMENTAL
Intervention: PDA-based evaluation forms
Number of subjects: 176

Group type: COMPARATOR
Intervention: Printed evaluation forms
Number of subjects: 176
Study: 17596638

Group type: EXPERIMENTAL
Intervention: Morning or afternoon bright light exposure for 1 hr daily (Monday‐Friday) for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual indoor light
Number of subjects: 0
Study: 12569202

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: N-HRT
Number of subjects: 38
Study: 10687880

Group type: EXPERIMENTAL
Intervention: HRT group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU/day) + calcium lactate (500 mg/day) (n = 232)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Non-HRT group: Calcium lactate (500 mg/day) alone or in combination with vitamin D3 (100-300 IU/day) (n = 232)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Both groups (HRT and non-HRT)
Number of subjects: 464
Study: 9210905

Group type: EXPERIMENTAL
Intervention: BCG (intravesical instillation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BLP (lactobacillus casei preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bropirimine (interferon inducer)
Number of subjects: 0
Study: 8398322

Group type: EXPERIMENTAL
Intervention: Ondansetron (3 doses of 8 mg IV at 0, 4, and 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide (3 mg/kg IV loading dose followed by 0.5 mg/kg/h for 8 hours)
Number of subjects: 0
Study: 3081361

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 80 mg aerosolized
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31729930

Group type: COMPARATOR
Intervention: Not applicable (participants declined intervention)
Number of subjects: 15
Study: 30257802

Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg orally daily for 12 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 65
Study: 27282594

Group type: EXPERIMENTAL
Intervention: Radial ESWT with 2000 shock waves/session of 0.2 mJ/mm(2) (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local methylprednisolone injections (n=20)
Number of subjects: 40
Study: 24676373

Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure) at 6 cmH2O for 30 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (placebo at 0-1 cmH2O)
Number of subjects: 23
Study: 22295869

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 20 mg/kg PO q8h for 16 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20738476

Group type: EXPERIMENTAL
Intervention: Commercially funded trials (pharmaceutical companies)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-commercial trials
Number of subjects: 105
Study: 19255990

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (10, 5, 5 mg/kg every 24 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension
Number of subjects: 62
Study: 16186612

Group type: EXPERIMENTAL
Intervention: Criteria-based learning method
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Clinical-research-and-experience-based learning method
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 12538432

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 10
Study: 10391155

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative radiotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME) without preoperative radiotherapy
Number of subjects: 500
Study: 9014674

Group type: COMPARATOR
Intervention: Stripping of the long saphenous vein
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sequential avulsion of the long saphenous vein
Number of subjects: 80
Study: 1345141

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study: 6435067

Group type: EXPERIMENTAL
Intervention: tinnitus masker
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: tinnitus instrument (a combination device consisting of a tinnitus masker and a hearing aid)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: hearing aid
Number of subjects: 34

Group type: COMPARATOR
Intervention: conventional environmental controls
Number of subjects: 34
Study: 31381593

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 300
Study: 30001740

Group type: EXPERIMENTAL
Intervention: DMARD treatment (starting with methotrexate monotherapy with prednisolone bridging)
Number of subjects: 217

Group type: COMPARATOR
Intervention: ACPA reactivity-positive patients
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: ACPA reactivity levels
Number of subjects: 217
Study: 26511599

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 8561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8561
Study: 24812043

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg or 1.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular interferon β‐1a (IFNβ‐1a)
Number of subjects: 0
Study: 22421598

Group type: EXPERIMENTAL
Intervention: Lispro mix 25 (LM25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 80
Study: 21045965

Group type: EXPERIMENTAL
Intervention: Ponseti methods (PCG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Extensive soft tissue surgery (NPCG)
Number of subjects: 105
Study: 18809617

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 482

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study: 16296571

Group type: EXPERIMENTAL
Intervention: Pager intervention (7 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting list control (baseline and post-pager phase)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Baseline (2 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Post-pager phase (2 weeks)
Number of subjects: 63
Study: 11990517

Group type: EXPERIMENTAL
Intervention: Physician-assessed quality of life parameters (toxicity and physical performance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLQ-C30 nausea/vomiting and diarrhea scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 0
Study: 9485087

Group type: EXPERIMENTAL
Intervention: 20 microg/day oral type II collagen (CII)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 100 microg/day oral type II collagen (CII)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 500 microg/day oral type II collagen (CII)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 2,500 microg/day oral type II collagen (CII)
Number of subjects: 274
Study: 7894459

Group type: EXPERIMENTAL
Intervention: Interaction with an attractive male partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction with an attractive female partner
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-encounter control situation
Number of subjects: 0
Study: 2548552

Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg oral)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Angiotensin I (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin I (after cilazapril)
Number of subjects: 7
Study: 811302

Group type: EXPERIMENTAL
Intervention: Interparietal instillation of povidone-iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated, randomized, matched controls
Number of subjects: 0
Study: 30883882

Group type: EXPERIMENTAL
Intervention: Calcium, vitamin D, and genistein
Number of subjects: 2

Group type: COMPARATOR
Intervention: Calcium and vitamin D
Number of subjects: 2
Study: 28086917

Group type: EXPERIMENTAL
Intervention: Resveratrol (up to 1 g by mouth twice daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 26338810

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25/5 mg
Number of subjects: 281
Study: 23632318

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma (DSCA: 70%)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Defunctioning stoma (TME-trial: 57%)
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Anastomotic leakage (DSCA: 12.1%)
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Postoperative mortality (DSCA: 1.1%)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Postoperative mortality (TME-trial: 3.9%)
Number of subjects: 1880
Study: 21318928

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural health-promotion intervention
Number of subjects: 1057

Group type: COMPARATOR
Intervention: HIV/STD risk-reduction intervention (Control)
Number of subjects: 1057
Study: 19958431

Group type: EXPERIMENTAL
Intervention: Jessner's solution peel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid peel 20%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical hydroquinone 2% and kojic acid
Number of subjects: 45
Study: 17063961

Group type: EXPERIMENTAL
Intervention: PC-based risk awareness and perception training program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untrained novice drivers
Number of subjects: 48
Study: 10545589

Group type: EXPERIMENTAL
Intervention: Dexamethasone (group I, 182 infants)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo (group II, 189 infants)
Number of subjects: 371
Study: 9074278

Group type: EXPERIMENTAL
Intervention: Microstop-treated bedding (Group 1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional bedding (Group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Old bedding (Group 3)
Number of subjects: 71
Study: 1715809

Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 10.0 ml
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 5.0 ml
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 2.5 ml
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Overall infestation rate 5 months after treatment
Number of subjects: 1527
Study: 6612232

Group type: EXPERIMENTAL
Intervention: Vas occlusion by tantalum clips without transection of the vasa
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional vasectomy by transection and ligation
Number of subjects: 68
Study: 30776996

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13126

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13126

Group type: EXPERIMENTAL
Intervention: Ticagrelor and Aspirin
Number of subjects: 13126
Study: 28815733

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional amphotericin B (Fungizone®)
Number of subjects: 12
Study: 26546476

Group type: EXPERIMENTAL
Intervention: Testimonial-based intervention on drowning risk
Number of subjects: 280

Group type: COMPARATOR
Intervention: Dog-bite risk (control)
Number of subjects: 280
Study: 24257149

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 2039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2039
Study: 22826530

Group type: COMPARATOR
Intervention: Ropivacaine 0.5% (10 mL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with dexmedetomidine 1 μg/kg (10 mL)
Number of subjects: 14
Study: 20088935

Group type: EXPERIMENTAL
Intervention: YM150 5 mg
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: YM150 10 mg
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: YM150 30 mg
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: YM150 60 mg
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: YM150 120 mg
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 1017
Study: 17611320

Group type: EXPERIMENTAL
Intervention: rhIL‐11 (1.5mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 24
Study: 16076946

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30
Study: 12084136

Group type: EXPERIMENTAL
Intervention: Brief interventions (5 to 60 minutes duration)
Number of subjects: 554

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 554
Study: 10463404

Group type: EXPERIMENTAL
Intervention: Drop test with varying test solutions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Drop test
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Drop test with increased viscosity of test solution
Number of subjects: 63
Study: 8531592

Group type: EXPERIMENTAL
Intervention: Somatostatin 100 micrograms bolus
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Somatostatin 250 micrograms bolus
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of bolus (250 micrograms) and infusion (250 micrograms/h for 65 min) of somatostatin
Number of subjects: 17
Study: 2083047

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.03% triclosan and 0.25% copolymer (Gantrez)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water placebo mouthrinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plax antiplaque prebrushing dental rinse
Number of subjects: 60
Study: 29902225

Group type: EXPERIMENTAL
Intervention: Meal rich in rapeseed oil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meal rich in palm oil
Number of subjects: 10
Study: 26814251

Group type: EXPERIMENTAL
Intervention: Alternative method of local anesthesia injection
Number of subjects: 127

Group type: COMPARATOR
Intervention: Traditional method of local anesthesia injection
Number of subjects: 127

Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Treatment needle size
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Pain at one inch of treatment needle insertion
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline pain
Number of subjects: 127
Study: 25123560

Group type: EXPERIMENTAL
Intervention: Visual diagnosis by operating urologist
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Visual diagnosis by operating urologist (specifically for muscle invasive cancer)
Number of subjects: 311
Study: 22156231

Group type: EXPERIMENTAL
Intervention: HEALTHY physical education intervention
Number of subjects: 21
Study: 20570604

Group type: EXPERIMENTAL
Intervention: Unloaded arm cycling exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unloaded leg cycling exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 10
Study: 17696680

Group type: EXPERIMENTAL
Intervention: Cash-based incentives ($50 and $100)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Goods-based incentives (vouchers)
Number of subjects: 12

Group type: COMPARATOR
Intervention: $100 checks (cash-based incentives)
Number of subjects: 12
Study: 15614703

Group type: EXPERIMENTAL
Intervention: Atovaquone-Azithromycin
Number of subjects: 369

Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 369
Study: 12394202

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide, applied to each nostril, once daily for eight weeks
Number of subjects: 145
Study: 9934299

Group type: EXPERIMENTAL
Intervention: Individual 15-minute educational presentations based on academic detailing
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 8610775

Group type: EXPERIMENTAL
Intervention: 2 mg of intravaginal prostaglandin E2 gel for 5 consecutive days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 5 consecutive days
Number of subjects: 100
Study: 2191763

Group type: EXPERIMENTAL
Intervention: Radiation therapy (2500 cGy over 5 to 7 days)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 849
Study: 367574

Group type: EXPERIMENTAL
Intervention: CAMF (Cyclophosphamide, Adriamycin, Methotrexate, 5-Fluorouracil)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CMF with Adriamycin at progression
Number of subjects: 78
Study: 31055568

Group type: EXPERIMENTAL
Intervention: MBP + OABP group
Number of subjects: 254

Group type: COMPARATOR
Intervention: OABP alone group
Number of subjects: 254
Study: 28836895

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHIP‐CE:PRF Achievement and Risk Avoidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guanfacine extended-release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osmotic‐release methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 0
Study: 28291972

Group type: EXPERIMENTAL
Intervention: Augmentative rTMS
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 93
Study: 26501260

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 grams daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24005198

Group type: EXPERIMENTAL
Intervention: Open reduction and plate fixation
Number of subjects: 200
Study: 21496800

Group type: EXPERIMENTAL
Intervention: Mind/body program (MB)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 19781471

Group type: EXPERIMENTAL
Intervention: Aspiration of residual lens epithelial cells (Group A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No aspiration of residual lens epithelial cells (Group B)
Number of subjects: 2